Kalaris Therapeutics Reports 2025 Financials and Key Clinical Updates
Kalaris Therapeutics Reports 2025 Full-Year Financial Results and Provides Significant Clinical and Corporate Updates
Highlights for Investors
- Positive Initial Clinical Data: Kalaris announced encouraging results from its Phase 1a trial of TH103 in neovascular Age-related Macular Degeneration (nAMD), showing meaningful improvements in visual acuity, retinal anatomy, and safety profile.
- Upcoming Catalysts: Preliminary data from the ongoing Phase 1b/2 study are expected in the first half of 2027, with plans to initiate Phase 3 clinical trials by year-end 2027.
- Strengthened Cash Position: The company completed a \$50 million oversubscribed private placement in December 2025, ending the year with \$118 million in cash, cash equivalents, and marketable securities.
- Financial Runway Extended: Current cash reserves are expected to fund operations into Q4 2027, covering key clinical milestones.
- Corporate Transformation: 2025 marked Kalaris’s transition to a public company, the completion of a merger with AlloVir, and significant operational expansion.
Key Business and Clinical Updates
Clinical Progress
-
Phase 1a Results (nAMD):
- Single intravitreal injection of TH103 at three dose levels (0.5 mg, 1.5 mg, 2.5 mg) in treatment-naïve nAMD patients.
- Thirteen patients completed 6 months of follow-up, showing:
- Mean 10-letter improvement in best corrected visual acuity (BCVA).
- Mean 129μm reduction in central subfield thickness (CST).
- Approximately 95% reduction in central subfield intraretinal fluid.
- 27- to 51-fold lower mean plasma Cmax compared to current leading anti-VEGF agents.
- TH103 was generally well tolerated—no dose-limiting toxicities or treatment-related serious adverse events observed.
- Pharmacokinetic profile supports the drug’s engineered properties, including prolonged intraocular residence time.
-
Phase 1b/2 Study:
- Ongoing multi-ascending dose, dose-finding study evaluating four monthly loading doses of TH103.
- Aims to assess safety and efficacy of repeat dosing and select optimal regimen for potential Phase 3 studies.
- Preliminary data readout anticipated in 1H 2027—an important upcoming catalyst.
Strategic and Financial Developments
-
Private Placement and Capital Raise:
- Closed an oversubscribed private placement for \$50 million in December 2025.
- Cash, cash equivalents, and marketable securities rose from \$1.6 million at December 2024 to \$118 million at year-end 2025, mainly due to the AlloVir merger and capital raise.
- Runway expected into Q4 2027, supporting advancement through key clinical milestones, including potential Phase 3 initiation.
-
Research and Development Expenses:
- R&D expenses were \$30.8 million for 2025, down from \$45.0 million in 2024. The decrease reflects a \$32 million royalty obligation in 2024 related to a Samsara BioCapital agreement, offset by increased clinical and manufacturing costs in 2025.
-
General and Administrative Expenses:
- G&A expenses rose to \$15.4 million from \$6.7 million in 2024, primarily due to higher insurance, legal, accounting, professional fees, and staff costs associated with operating as a public company.
-
Net Loss:
- Net loss for 2025 was \$43.4 million, a material improvement from \$69.2 million in 2024, reflecting lower R&D royalty costs and increased financial discipline.
- Shares outstanding as of December 31, 2025: 22,902,418.
Other Noteworthy Items for Shareholders
- Kalaris’s strong cash position, reduced net loss, and upcoming clinical data readouts are likely to be price-sensitive and may act as catalysts for share price movement in the coming quarters.
- Transition to a public company and successful capital raise bolster credibility and resources for late-stage clinical development and potential commercialization.
- Any delays or setbacks in Phase 1b/2 or future Phase 3 studies, or failure to meet clinical endpoints, remain key risks that could negatively impact share value.
- Competition, intellectual property, and regulatory risks are explicitly acknowledged by management as forward-looking uncertainties.
About Kalaris Therapeutics
Kalaris Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for retinal diseases. The company was founded by Dr. Napoleone Ferrara, a pioneer in anti-VEGF therapy. Kalaris’s lead program, TH103, seeks to address significant unmet needs in sight-threatening retinal conditions.
For more information, visit www.kalaristx.com.
Investor Contact
Disclaimer: This article contains forward-looking statements based on current expectations, projections, and assumptions of Kalaris Therapeutics management. Actual results may differ materially due to risks and uncertainties related to clinical development, regulatory approval, capital requirements, and other factors. Investors should review risk factors in Kalaris’s public filings and not rely solely on this summary for investment decisions.
View Kalaris Therapeutics, Inc. Historical chart here
